Despite Endpoint Furor, FDA Panel Unanimously Backs Vanda’s Hetlioz
A meeting of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that Vanda Pharmaceuticals Inc.’s candidate for non-24-hour sleep-wake disorder, Hetlioz (tasimelteon), was safe and voted 10-0, with one abstention, that the company provided substantial evidence of efficacy for the drug.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST